Please assess the completion status of the following clinical trial:

Trial Title: Catheter Ablation vs. Medical Therapy in Congested Hearts With AF

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* must be 18 years of age or older~* Provide signed written Informed Consent~* symptomatic AF documented by EKG or heart rhythm monitoring within 12 months~* patients should be on optimal medical therapy for heart failure for 3 months prior to randomization. Adjustments to medications within this 3 month period are permitted.~* chronically impaired LV function defined as EF between 20%-45% within last 3 months~* all patients should be on an optimal therapy for impaired LV function~* ability to complete 6 minute walk test~* eligible for catheter ablation and anti-arrhythmic drugs~Exclusion Criteria:~* women of childbearing potential unless post- menopausal or surgically sterile~* patients hospitalized for heart failure within the 3 months prior to randomization~* reversible causes of AF such as pericarditis, thyroid disorders, acute alcohol intoxication, recent major surgical procedures or trauma~* recent reversible LV impairment that may be attributed to AF with rapid ventricular response and may improve with introduction of rate control~* valvular heart disease requiring surgical intervention~* Coronary Artery Disease (CAD) requiring surgical or percutaneous intervention~* early post-operative AF (within 3 months of surgery)~* previous MAZE or left atrial instrumentation (including ablation and left atrial appendage exclusion)~* history of Atrioventricular Node (AVN) ablation~* hypertrophic cardiomyopathy~* prolonged QT interval~* liver failure~* renal failure requiring dialysis~* social factors that would preclude follow up or make compliance difficult- history of drug, alcohol or substance abuse~* contraindications to the use of AADs and/or anticoagulation therapy~* Currently enrolled in, or discontinued within the last 30 days from a clinical trial involving an investigational product or non-approved use of a drug or device or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.~* severe pulmonary disease~* documented intra-atrial thrombus, tumor, or structural abnormality which precludes catheter introduction~* unwilling to comply with protocol requirements or deemed by the investigator to be unfit for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AF catheter Ablation (Type: ACTIVE_COMPARATOR): Pulmonary Vein Isolation catheter ablation for treatment of AF. AF catheter ablation is an FDA approved treatment for AF
- FDA approved anti arrhythmic drug (Type: ACTIVE_COMPARATOR): FDA approved anti arrhythmic drug for the treatment of AF will be based on treating physicians' preference in accordance to guidelines.

Based on this trial design, predict the completion outcome and termination type (if applicable).